Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02445651 · ClinicalTrials.gov registry record · NA

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

A NA study of Parkinson Disease and Idiopathic Parkinson Disease, sponsored by Thomas Jefferson University.

Completed
Registry status
NA
Development phase
51
Enrollment target
1
Study location

NCT02445651 is a NA study of Parkinson Disease and Idiopathic Parkinson Disease that has completed, run by Thomas Jefferson University. The registered enrollment target is 51 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02445651, a NA study of Parkinson Disease and Idiopathic Parkinson Disease, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
NA
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

Parkinson's disease (PD) is a neurodegenerative disorder of unknown cause that affects more than a million Americans. It's most prominent pathology is the degeneration of dopaminergic neurons in the brain. It is believed that oxidative stress and inflammation play an important role in the pathophysiology of Parkinson's disease as well. The object of this study is to evaluate whether nutritional supplementation with oral and IV N acetyl cysteine compounds, that have been shown to have either anti- inflammatory, or antioxidant effects, might support brain function in patients with Parkinson's disease, particularly in regards to the dopamine system. Enrolled patients will be randomly assigned to receive oral and intravenous (IV) n-acetyl cysteine (NAC), a control group of standard PD care, or an oral supplement group who will receive Oral Supplements Cohort Baicalin, Ganoderma, Omega 3 and Curcumin. (Please note, the Oral Supplements arm, was amended and not included in analysis. This study utilized Ioflupane (DaTscan) single photon emission computed tomography (SPECT) to measure dopamine function, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD. Subjects received a DaTSCAN and MRS initially and after completing oral and IV NAC regimen. Subjects in the control group received pre and post DaTScans and MRS and similar evaluations to the Dietary Supplement oral and IV NAC group.

Interventions

  • OTHER Control group
  • DIETARY_SUPPLEMENT Intravenous and Oral n-acetyl cysteine
  • DIETARY_SUPPLEMENT Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2014-03
Est. Completion 2022-08-04
Phase NA

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT02445651

The ClinicalTrials.gov registry entry for NCT02445651 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which Control group is the first listed.

NCT02445651 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02445651 about?

NCT02445651 is a clinical study titled "Physiological Effects of Nutritional Support in Patients With Parkinson's Disease". Parkinson's disease (PD) is a neurodegenerative disorder of unknown cause that affects more than a million Americans. It's most prominent pathology is the degeneration of dopaminergic neurons in the brain. It is believed that oxidative stress and inflammation play an important role in the pathophysi...

What is the current status of trial NCT02445651?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2014-03. Estimated completion is 2022-08-04.

What conditions does trial NCT02445651 study?

This clinical trial studies the following conditions: Parkinson Disease, Idiopathic Parkinson Disease.

What interventions are being tested in trial NCT02445651?

The interventions under investigation include: Control group (OTHER), Intravenous and Oral n-acetyl cysteine (DIETARY_SUPPLEMENT), Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02445651?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02445651 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.